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Three NOD2 polymorphisms (single nucleotide polymorphism [SNP]8 [2104C>T, Arg702Trp], SNP12
[2722G>C, Gly908Arg], and SNP13 [3020insC, Leu1007 fsins C]), identiﬁed as disease-associated variants in
Crohn’s disease, have recently been suggested as gene markers of the outcome of hematopoietic stem cell
transplantation (HSCT). In the present multicenter study of 464 donor-recipient pairs, we focused on the
effect of NOD2 mutation(s) on the risk of infections and acute graft-versus-host disease (aGVHD). The
presence of SNP13 in recipients, donors, or both was more frequently seen in patients having sepsis than in
those lacking sepsis (9 of 48 versus 33 of 386, P ¼ .046). The presence of SNP8 (recipient and/or donor
positive) was associated with a higher rate of Herpes viruses reactivation (17 of 21 versus 86 of 173, P ¼ .007).
In the SNP8-positive group, a trend for a higher rate of bacteremia well controlled by antibiotics was found (9
of 10 versus 47 of 81, P ¼ .106). In contrast, the presence of SNP13 in recipient and/or donor resulted in a poor
response to antibiotics (5 of 11 versus 9 of 10, P ¼ .042). A statistically signiﬁcant association between the
presence of NOD2 SNPs and acute grade > II GVHD was found in a subgroup of HSCT patients who received
transplants from unrelated donors with a myeloablative conditioning regimen that included antithymocyte
globulin (ATG). In this subgroup of patients, donor positivity for any SNPs investigated (7 of 18 versus 17 of
113, P ¼ .036) and, independently, only the presence of SNP8 (4 of 8 versus 20 of 123, P ¼ .055) were asso-
ciated with severe grade  II aGVHD. In conclusion, SNP8 positivity in donors or recipients makes patients
more prone to Herpes viruses reactivation and bacteremia but not to sepsis. Septic complications were
associated with SNP13 polymorphism. SNP8 in donors constitutes a risk factor of severe aGVHD, but only if
patients received transplants from unrelated donors and received ATG as part of a conditioning regimen.
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quests: Andrzej Lange, MD, L. Hirszfeld
erimental Therapy, Polish Academy of
mmunology, Rudolf Weigl 12, 53-114
wroc.pl (A. Lange).
2014 Published by Elsevier Inc. on behalf of Am
13.12.558INTRODUCTION
The innate immune system constitutes the ﬁrst line of
defense against bacterial and fungal infections. The recog-
nition system depends on sensing some microbial structures
that are reactive with membrane and cytosol patternerican Society for Blood and Marrow Transplantation.
E. Jaskula et al. / Biol Blood Marrow Transplant 20 (2014) 409e414410recognition receptors [1]. Among these is the NOD2/CARD15
receptor, which recognizes muramyl dipeptide (MDP), pro-
teoglycans, and lipopolysaccharide, all present in Gram
positive and negative bacteria [2]. A more recent study
documented that this receptor is also triggered by viral single
strand RNA [3].
NOD2 is present in macrophages, dendritic cells, intesti-
nal epithelial cells [4], T cells [5], NK cells, and CD34þ he-
matopoietic progenitor cells [5].
Evolution takes advantage of the incidental substitution
of a single nucleotide by another one (single nucleotide
polymorphism, [SNP]), which may change the transcription
potential or codons of a mutated gene. Point mutations of-
fering some beneﬁt of survival are preserved and, if they are
present in 5% of the population, are recognized as alleles.
In the human NOD2 gene, 854 SNPs have been identiﬁed
(dbSNPeNCBI, June 2013). In this study, we focused on NOD2
polymorphisms associated with Crohn’s disease (CD) located
in or near the leucine-rich region (LRR) of the NOD2 gene: (1)
C/T transition at position 2104dSNP8 (2104C>T, Arg702Trp);
(2) C/G transversion at position 2722dSNP12 (2722G>C,
Gly908Arg); and (3) cytosine insertiondSNP13 (3020insC,
Leu1007fsinsC), which results in formation of a stop codon
and, consequently, in the deletion of 33 amino acids [6]. The
LRR domain binds microbial pattern molecules passing on
signals through RIP2 (Receptor Interacting Protein 2) and
TRAF 6 (TNF Receptor-Associated Factor 6) [7,8]. Both the
ability of microbial pattern recognition and the downstream
signaling are affected by LRR domain mutations of the NOD2
gene. Mutated NOD2 (SNP13) recognizes lipopolysaccharide
but not MDP [9,10].
Hematopoietic stem cell transplant (HSCT) recipients are
susceptible to microbial infections, including viral reac-
tivation due to the period of weeks inwhich there is a lack of
optimal number of both innate and adaptive immunity
involved cells. Several papers on the role of NOD2 mutation
in the course of HSCT have not brought conclusive results so
far [11-17]. Most of the authors analyzed the incidence of
aGVHD, rather than infections.
Therefore, in the present study we focused on the
following: (1) assessment of the adverse effect of NOD2 mu-
tation(s) on the risk of infections, (2) the possible additive
effect of an adaptive immunity deprivation (in vivo T cell
purging) on NOD2 mutation risk factors, and (3) separate
analysis of the effect of the 2most commonNOD2 alleles (SNP8
and SNP13) on both infections and aGVHD. To properly address
these questions, we conducted a well-standardized multi-
center study, which collected 464 patients and their donors.
PATIENTS AND METHODS
Patient Characteristics
Patients receiving allogeneic HSCT (alloHSCT) in 6 clinical
units (Lower Silesian Center for Cellular Transplantation,
Silesian Medical University, Medical University of Warsaw,
Medical University of Gdansk, Medical University of Lublin,
and University Children’s Hospital in Cracow) from the year
2000 until 2012 constituted the cohort of this study.
A total of 464 patients (204 female, 261 male; 38 and 426
patients were below and above 16 years of age, respectively;
399 with malignant disease and 51 with nonmalignant dis-
eases) allografted from 380 unrelated (MUD) and 84 sibling
(SIB) donors were studied. Of these, 254 and 183 patients
received myeloablative and reduced-intensity conditioning
(RIC), respectively. A total of 315 recipients received for in
vivo T cell-purging antilymphocyte antibodies (n ¼ 273,antithymocyte globulin [ATG, Fresenius, Munich, Germany],
and n ¼ 42, alemtuzumab [Campath, Genzyme, Cambridge,
MA]).
Transplantation indicationswere in linewith theEuropean
Group for Blood and Marrow Transplantation guidelines and
the searching process was conducted according to the World
Marrow Donor Association recommendations. Clinical infor-
mation was collected in a standardized fashion employing a
standard questionnaire adapted from the Minimum Essential
Data collection formof EuropeanGroup for Blood andMarrow
Transplantation but, in addition, included information on
conditioning, HLA speciﬁcities, transplantation-related toxi-
city, post-transplantation chimerism, and herpes and poly-
oma viruses post-transplantation infection/reactivation.
HLA matching was performed at the allele level of 5 loci
(A, B, C, DR, and DQ). Two hundred and sixty patients
received transplants from well matched (10 of 10) and 120
from poorly (<10 of 10) matched unrelated donors. Sibling
donorswere identical with the recipients in HLA, as shown by
appropriate typing followed by haplotype segregation. Un-
related donors received ATG in a cumulative dose of 10mg/kg
body weight (bw) to achieve a target value of 1.0% CD3þ cells
in peripheral blood, which was measured after 3 days of ATG
treatment. If the target was not achieved by the last day,
patients received ATG in an increased dose to 5 mg/kg bw.
Forty-two patients received Campath in a cumulative dose of
60 mg/kg bw.
In addition to in vivo T cellepurging cyclosporine A as an
intravenous injection (5 mg/kg bw) followed by an oral route
with a threshold value of 150 to 200 ng/mL was used as a
GVHD prophylaxis (145 patients) and, in 239 patients, in
addition, a short course of methotrexate was given. Patients
who received transplants from sibling donors received ATG
only when nonmyeloablative conditioning was employed
(15 patients). Table 1 summarizes patient characteristics.
The overall incidence of aGVHD grade I to IV and grade
III to IV was 46.0% and 11.4%, respectively.
Diagnosis of sepsis, in addition to positive blood culture,
was supported by the presence of general symptoms (fever>
38.3C, heart rate > 90/min, tachypnea, and altered mental
status) and organ failure with oliguria, hypoxemia, and
arterial hypotension.
Cytomegalovirus (CMV), Epstein Barr virus (EBV), and
human herpesvirus 6 (HHV6) infection/reactivation events
were studied in 201 patients (134 SIB and 67 MUD) who
underwent transplantation at the Lower Silesian Center for
Cellular Transplantation. Viral DNA copies were determined
before and then at 1-week intervals after HSCT until 30 days
after transplantation, then monthly up to 1 year, and at any
time when reactivation of studied viruses was suspected. Of
all the patients, 52.7% had at least 1 infection/reactivation
event (CMV [27.8%], EBV [23.4%], HHV6 [17.6%]) within 1 year
after HSCT, and 62.1% of patients with herpes virus (EBV,
CMV, or HHV6) reactivation/infection had a fatal outcome,
compared with 42.4% of patients without herpes infection
events (P ¼ .042). CMV infection/reactivation was associated
with the presence of aGVHD > grade I (25 of 56 versus 37 of
143, P ¼ .011, chi-square test).
Materials and Methods
DNA was extracted from peripheral blood in 461 patients and 460 do-
nors before hematopoietic stem cell transplantation (4 donor samples and 3
recipients were missed).
NOD2 genotyping (SNP8 [2104C>T, Arg702Trp], SNP12 [2722G>C,
Gly908Arg], and SNP13 [3020insC, Leu1007fsinsC]) was determined in 2
laboratories and performed using real-time end point genotyping with
Table 1
Patients’ Characteristics
Characteristic Value
No. of patients 464
Age, median (range), yr 32 (.6-60)
Adults > 16 yrs 426
Children  16 yrs 38
Recipient gender
Female 204
Male 260
Donor gender
Female 188
Male 271
Donors
Sibling 84
MUD 10/10 allele matched 260
MUD allele or low resolution level mismatched 120
Transplant material
Bone marrow 114
Peripheral blood progenitor cells 331
Diagnosis
Hematological malignancies 399
Anemias 33
Immunodeﬁciencies 17
Cancer testis 1
Donor CMV serostatus
CMV IgG  191
CMV IgG þ 246
Recipient CMV serostatus
CMV IgG  94
CMV IgG þ 349
Donor/recipient IgG CMV serostatus
Rþ/D 133
Rþ/Dþ 209
R/D 57
R/Dþ 37
Conditioning regimen
Myeloablative 183
Reduced-intensity conditioning 254
Acute GVHD, grades
0 236
I 83
II 69
III 24
IV 26
NOD2/CARD15 polymorphism
Recipient
SNP8 32 of 461 (.069)
SNP12 16 of 461 (.034)
SNP13 32 of 461 (.069)
Total 69 of 461 (.150)
Donor
SNP8 39 of 460 (.085)
SNP12 24 of 460 (.052)
SNP13 27 of 460 (.059)
Total 89 of 460 (.193)
Donor or recipient NOD2 polymorphism present 147 of 460 (.319)
Donor and recipient NOD2 polymorphism present 23 of 460 (.050)
MUD indicates matched unrelated donor; CMV, cytomegalovirus; D, donor;
R, recipient; GVHD, graft-versus-host disease; SNP, single nucleotide poly-
morphism.
Data presented are (n), unless otherwise indicated.
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(RFLP) assays. This technique provides fully comparative results, which was
veriﬁed by detection of NOD2 polymorphisms in 96 samples with 2 assays
having exactly the same result. Real-time genotyping was performed with
primer and probe sequences and protocols according to Hampe et al. [18].
Fluorescence signals were detected in a Light Cycler 480 II (Roche, Basel,
Switzerland) instrument using the end point detection approach (according
to the manufacturer’s instructions).
In PCR RFLP assays, 130, 261, and 270-bp-long fragments of the NOD2/
CARD15 gene were ampliﬁed for SNP8, 12, 13 polymorphisms, respectively,
using primers with the sequence given in Table 2.
The PCR cycling conditions were as follows: 94C for 3 minutes, fol-
lowed by 40 cycles of 94C for 30 seconds, 60C for 30 seconds, 72C for 30seconds, with a ﬁnal elongation step at 72C for 10 minutes. The PCR
products were analyzed by electrophoresis in a 2.5% agarose gel with
ethidium bromide and visualized under UV. Then, the PCR products speciﬁc
for the NOD2/CARD15 gene were digested (3 hours, 37C) withMspI or HhaI
or NlaIV restriction endonucleases (Euryx, Gdansk, Poland), for SNP8, 12, 13
respectively, and analyzed in 3% agarose gel. Lengths of enzyme cleavage
products are given in Table 2.
Numbers of CMV, EBV, and HHV6 DNA copies present in blood were
determined according to the procedure described elsewhere [19]. The
sequence of the PCR primers and the probe were selected from the BALF5
region of EBV, the US17 region of CMV, and the U67 region of HHV6.Statistical Analysis
STATISTICA v.10 was used for chi-square, chi-square with
Yates’ correction, V-square or Fisher’s exact test, if appro-
priate [20], and overall survival analysis (Kaplan-Meier and
log-rank tests) or logistic regression in multivariate analysis.
Genotype frequencies observed in donors and recipients
were compared with Hardy-Weinberg expectations using
chi-square test statistics. The likelihood of committing a type
1 error was set to .05.RESULTS
Frequency Distribution of NOD2/CARD15 Polymorphisms
There were no differences regarding the frequencies of
SNP8,12, and 13 carriers in donors and recipients (SNP8, 8.5%
versus 6.9%; SNP12, 5.2% versus 3.4%; SNP13, 5.9% versus
6.9%, for donors and recipients, respectively) (Table 1).
At least 1 out of 3 studied SNPs was found in 89 donors
(19.3%) and 69 recipients (15.0%). Notably, all individuals
except 1 were heterozygotes. In 147 (31.9%) and in 23 (5.0%)
donor-recipient pairs, 1 out of 3 studied SNPs was found
either in a donor, in a recipient, or in both. The observed
genotype frequencies for all NOD2/CARD15 variants in donors
and recipients were consistent with the Hardy-Weinberg
equilibrium.NOD2 Mutations and Infectious Risk in Patients
Receiving Transplants from Siblings and Unrelated
Donors
In the whole group, 191 patients (41%) died after HSCT. In
188 patients (99%), the cause of death was documented.
Altogether, 107 patients died because of infections. Among
those, 37 and 70 had sepsis or organ infections, respectively.
Notably, GVHD (acute or chronic) was less frequent in pa-
tients with sepsis than with organ infections (6 of 37 versus
28 of 70, P ¼ .022, chi-square test with Yates’ correction).
Forty-four, 25, and 12 patients died because of relapse, pro-
gressive GVHD, and transplantation-related toxicity, respec-
tively. The presence of NOD2 SNPs did not affect overall
survival, if present either in donors or in recipients; however,
if both donor and recipient had NOD2 polymorphism(s), the
survival curve was signiﬁcantly poorer as compared with
others (36% versus 58% P ¼ .050, 5-year survival) (Figure 1).
The other important observation is that the presence of
SNP13 either in recipient, in donors, or in both was more
frequently seen in patients with sepsis as compared with
patients not having post-transplantation septic complica-
tions (9 of 48 versus 33 of 386, P ¼ .046, chi-square test with
Yates’ correction). In contrast, similar positivity for SNP8 was
associated with a higher rate of Herpes viruses reactivation
(17 of 21 versus 86 of 173, P¼ .007, chi-square test) but not to
a signiﬁcant level with a risk of bacteremia (9 of 10 versus
47 of 81, P ¼ .106, chi-square test with Yates’ correction).
Table 2
Sequence and PCR Products in Restriction Enzyme Cleavage in PCR RFLP NOD2/CARD15 Genotyping
NOD2/CARD15
Polymorphism
Primer Sequences Length of
PCR Product
Restriction
Enzyme
Length of PCR Products after Restriction Enzyme Cleavage
SNP8 2104C>T Forward:
50- TTCCTGGCAGGGCTGTTGTC-30
Reverse:
50- AGTGGAAGTGCTTGCGGAGG - 30 [18]
130 bp MspI Homozygotes CC wild type Heterozygotes CT Homozygotes
TT
22 bp
55 bp
22 bp
55 bp
110 bp
22 bp
110 bp
SNP12 2722G>C Forward:
50- CCACTCTGGGATTGAGTGGT - 30
Reverse:
50- CTTCACCTGATCTCCCCAAG - 30 [18]
261 bp HhaI Homozygotes GG wild type Heterozygotes CG Homozygotes
CC
124 bp
261 bp
124 bp
137 bp
261 bp
124 bp
137 bp
SNP13 3020insC Forward:
50- TGGCTAACTCCTGCAGTCTCT - 30
Reverse:
50- CCTCAAAATTCTGCCATTCC - 30
270 bp NlaIV Homozygotes CC wild type Heterozygotes Cins C Homozygotes
insCins C
41 bp
90 bp
180 bp
41 bp
90 bp
139 bp
180 bp
41 bp
90 bp
139 bp
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responded more poorly to antibiotics as compared to those
with SNP8 (5 of 11 versus 9 of 10, P ¼ .042, Fisher exact test).
Multivariate analysis showed that SNP13 (in donors and/or
recipients) was statistically signiﬁcant (odds ratio [OR] ¼ 2.60,
P ¼ .030) as a risk factor of sepsis. Risk of sepsis was not
associated with use of ATG (OR ¼1.72, P ¼ .183) and the pres-
ence of SNP8 (in donor and/or recipient) (OR ¼1.83, P ¼ .178).
For Herpes viruses reactivation, donor negative and
recipient positive CMV IgG serostatus before HSCT (OR ¼
2.699, P ¼ .009) and the presence of SNP8 in donor and/or
recipient (OR ¼ 4.518, P ¼ .010) were found to play inde-
pendent and signiﬁcant roles.
In conclusion, we provided strong evidence that the
presence of SNP8 in donors or recipients is associated with
bacteremia of favorable course and the same mutation
makes patients more prone to Herpes viruses reactivation,
but the presence of SNP 13 constitutes a signiﬁcant risk factor
of fatal sepsis.
NOD2 Mutations and aGVHD Risk in Recipients of
Unrelated Donor Transplants
Three hundred eighty patients received transplants from
unrelated donors. In this group, the presence of NOD2P = .050
Figure 1. Kaplan-Meier survival probability in a group of patients with NOD2
polymorphisms receiving transplants from NOD2 SNP positive donors
compared with their counterparts.mutation(s) (SNP8, 12, 13) in both donors and recipients
tended to be associatedwith a higher risk of severe aGVHD (4
of 13 versus 37 of 338, P ¼ .081, chi-square test with Yates’
correction) but not with the incidence of aGVHD of lower
grades.
The inﬂuence of NOD2 SNPs (8, 12, 13) in both donors and
recipients was stronger and statistically signiﬁcant in a sub-
group of recipients of MUD transplants who received ATG as
part of a conditioning regimen (4 of 7 versus 31 of 228, P ¼
.008, chi-square test with Yates’ correction). The latter sub-
group of patients were further analyzed. It appeared that the
presence of NOD2 SNPs at the donor site was signiﬁcantly
associated with a risk of severe grade > II aGVHD (10 of 38
versus 24 of 198, P ¼ .042, chi-square test with Yates’ correc-
tion). If the 3 investigated SNPs were analyzed separately,
SNP8-associated features appeared to be the main players. In
the analysis, neglecting the presence of SNP12 and 13 in do-
nors, SNP8 positivity in donors signiﬁcantly increased the risk
of severe aGVHD (6 of 17 versus 28 of 191, P¼ .029, chi-square
test with Yates’ correction).
In this ATG-receiving MUD patient group, there were 131
and 98 patients receiving myeloablative and reduced-
intensity conditioning, respectively. It appeared that an as-
sociation between donors’ positivity for any of the SNPs
investigated (7 of 18 versus 17 of 113, P¼ .036, chi-square test
with Yates’ correction) and separately SNP8 (4 of 8 versus 20
of 123, P ¼ .055, chi-square test with Yates’ correction) and
severe aGVHD was valid for patients on the myeloablative
but not on the reduced-intensity conditioning regimen.
Campath was used in patients with acute lymphoblastic
leukemia and in those with a higher risk of aGVHD. Because
of the last reason, patients on Campath were excluded from
the ATG group to avoid bias due to the higher immunosup-
pression potential of anti-CD52 monoclonal antibodies.
Indeed, all Campath-receiving patients suffered from Herpes
viruses reactivation if SNP8 were present in a donor-
recipient pair; this was found in only 11 out of 14 (not sig-
niﬁcant) in the ATG group.Multivariate Analysis
NOD2-associated features (SNPs at donor or recipient site
and donor SNPs, particularly SNP8) found to constitute a risk
of severe aGVHD in patients conditioned using ATG were
subjected to multivariate analysis together with the
following: (1) donor-recipient IgG CMV serostatus (donor
Table 3
Multivariate Analysis of Factors Inﬂuencing Severe aGVHD
aGVHD>II CMV IgG
Serostatus
(D-/ Rþ)
BM as a Source of
Transplant Material
HLA
Mismatch
SNP8
Polymorphism
in Donor
Coefﬁcient .799 1.267 .982 1.466
P Value .059 .048 .018 .017
Odds Ratio 2.224 .282 2.669 4.330
95% Cl .969 .080 1.182 1.308
þ95% Cl 5.109 .990 6.026 14.334
aGVHD indicates acute graft-versus-host disease; BM, bone marrow; CI,
conﬁdence interval; D, donor; R, recipient; CMV, cytomegalovirus.
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.013); (2) peripheral blood progenitor cells as a source of
transplant material (31 of 178 versus 4 of 64, P ¼ .029); and
(3) HLA mismatch (allele level) (18 of 85 versus 18 of 161, P¼
.035).
The following factors were found to be independent and
signiﬁcant risk factors of severe aGVHD: (1) donor SNP8
positivity (OR ¼ 4.330, P ¼ .017), (2) peripheral blood pro-
genitor cells as transplant material (OR ¼ 3.55, P ¼ .048), (3)
HLAmismatch (OR¼ 2.669, P¼ .018), and (4) donor-recipient
IgG CMV serostatus (OR ¼ .282, P ¼ .059) (Table 3).DISCUSSION
The number of papers published on the association be-
tween NOD2 polymorphisms and the outcome of HSCT has
been growing in recent years [12,13,16,17,21], since the very
ﬁrst publication of the studies by Holler et al. [22]. This
shows that the topic is still burning and no conclusion has
been reached so far. Holler et al. [23] and van den Velden
et al. [24] believe this is because of the poor standardization
of a number of studies neglecting the differences between
sibling and unrelated transplantation, as well as myeloa-
blative and RIC conditioning regimens, and the inﬂuence of
age and sex.
In 2009, we started collecting a cohort of patients who
underwent transplantation in 4 different transplantation
centers. Altogether, 464 individuals entered the cohort,
which included a good representation of patients assigned to
2 main transplantation modalities (SIB versus MUD) and
patients receiving 2 conditioning regimens (myeloablative
and RIC) (Table 1). From the methodological point of view,
NOD2 SNPs were investigated using 2 techniques: RFLP and
real-time end point genotyping PCR.
The ﬁrst attempt in the analysis of the data was to study
whether NOD2 SNPs affected the rate of bacterial complica-
tions. Analysis of the whole group (SIB and MUD HSCT on
myeloablation or RIC) documented that the presence in do-
nors and/or recipients of the frame shift mutation 1007fsinsC
(SNP13) was associated with a higher risk of death from
sepsis. This observation was the ﬁrst showing the adverse
effect of SNP13-associated features on the outcome of sepsis
in HSCT patients and it is in linewith previous studies carried
out on intensive care units patients and acute myeloid leu-
kemia patients [25-27]. The similarity of the results of these
3 studies showed that the biological effect of SNP13mutation
is similar in septic patients independently of the underlying
disease. In SNP13 carriers, membrane localization of NOD2 in
epithelial cell membrane is impaired, which provides easy
access for bacteria to enter the intestine wall [28,29]. This is
not the case in SNP8 carriers [8,28]. Indeed, we found that in
spite of a higher bacteremia rate in patients receiving orhaving SNP8, they responded well to antibiotics and
bacteremia did not progress to sepsis.
This is a novel observation that shows that both SNPs
make patients more susceptible to blood infection, but only
those with SNP13 are more prone to the cytokine cascade of
events leading to sepsis. Indeed, in a mouse study, but not in
humans [30], it was found that SNP13 is associated with
an increase in IL-1beta generation in response to MDP [8,31].
In man, SNP13 is associated with Crohn’s disease, which
is characterized by a striking inﬂammatory cytokine-
dependent process. In sepsis, the deteriorating effect of
cytokines is also known and the fatal course of sepsis was
seen in patients with SNP13.
The signal recognition of cytosol NOD2 may be similar to
that described for TLR3, TLR7, and TLR9, which recognize
nucleic acids released in the cell after bacterial and viral
internalization [31,32]. Moreover, NOD2 mediates anti-
inﬂammatory signals induced by TLR2, TLR3, and TR4 li-
gands [33,34]. This is of special interest in light of our
observation on the role of NOD2 mutation in Herpes viruses
reactivation risk. All these Toll-like receptors are involved in
recognition of virion components of EBV, CMV, Varicella
zoster virus, herpes simplex virus 1, and herpes simplex virus
2, including envelope glycoprotein (TLR2) and Herpes virus
dsRNA (TLR3) or ssRNA (TLR4) [35]. NOD2 is present in
monocytes/macrophages, target cells for CMV and lympho-
cytes, which are targeted by HHV6 and EBV. The putative
method of recognition of viral DNA in endosomes may help
explain the association of SNP8 with Herpes viruses reac-
tivation/infection. Up to now, only 1 paper has provided
proof that the NOD2 receptor can recognize viral ssRNA [3]. It
seems to be also valid for DNA of viruses. Herpes viruses have
long been suspected to be associated with aGVHD [36-39]. In
the present study, a similar association was found between
SNP8 and Herpes viruses reactivation, as well as an inde-
pendent association with aGVHD. CMV reactivation and
aGVHDwere found to associatewith each other (see also this
study). The present study results are generally in favor of the
view that the association with NOD2 SNPs, in particular
SNP8, is rather indirect and operates via increased incidence
of microbial infections, including bacteria and viruses.
Notably, an increased risk of aGVHD is valid only for MUD
patients, who were on myeloablative conditioning, including
ATG. These 2 factors, myeloablation and ATG, are known to
increase the risk of post-transplantation infections [40-42].
Interestingly, NOD2 SNPs at the donor but not at the
recipient site played a role as a risk factor of aGVHD. Indeed,
transplanted lymphocytes are those executing aGVHD
[43,44] and they are targeted by Herpes viruses [45,46].
In conclusion, the adverse effects of NOD2 poly-
morphisms are mostly associated with microbial infections
and reactivations, and the latter seem to be responsible for
increased risk of aGVHD in patients after HSCT.
The work on NOD2 SNPs may be helpful in planning
the antimicrobial surveillance of patients. Those with
SNP13 and SNP8 are more prone to fatal sepsis and viral
reactivation, respectively. Therefore, being aware of the
presence of SNPs may allow appropriate tailoring of anti-
infectious post-transplantation policies to improve the
survival of patients.ACKNOWLEDGMENTS
The authors thank all colleagues contributing to the
activity of the Polish Donor Recipient Matching Group.
E. Jaskula et al. / Biol Blood Marrow Transplant 20 (2014) 409e414414Financial disclosure: This study was supported by the
National Centre for Research and Development grant N R13
0082 06.
Authorship statement: E.J. performed genetic work and
statistical analysis and wrote the paper; A.L. designed of the
study and wrote the paper; P.C performed genetic work;
S.K.K., M.M., M.D.M., W.W.J., M.M.D., J.L., K.W., A.H., J.K., K.D.,
and J.G. provided medical data; A.G., J.N. provided HLA
typing; and S.M. provided data management and statistical
analysis.REFERENCES
1. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen
recognition. Int Immunol. 2009;21:317-337.
2. van der Meer JH, Netea MG, Dinarello CA. Modulation of muramyl
dipeptide stimulation of cytokine production by blood components.
Clin Exp Immunol. 2009;156:428-433.
3. Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune
antiviral responses by Nod2. Nat Immunol. 2009;10:1073-1080.
4. Gutierrez O, Pipaon C, Inohara N, et al. Induction of Nod2 in myelo-
monocytic and intestinal epithelial cells via nuclear factor-kappa B
activation. J Biol Chem. 2002;277:41701-41705.
5. Shaw MH, Reimer T, Sánchez-Valdepeñas C, et al. T cell-intrinsic role of
Nod2 in promoting type 1 immunity to Toxoplasma gondii. T cell-
intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma
gondii. Nat Immunol. 2009;10:1267-1274.
6. Russell RK, Nimmo ER, Satsangi J. Molecular genetics of Crohn’s disease.
Curr Opin Genet Dev. 2004;14:264-270.
7. Lecat A, Piette J, Legrand-Poels S. The protein Nod2: an innate receptor
more complex than previously assumed. Biochem Pharmacol. 2010;80:
2021-2031.
8. Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mu-
tations. Inﬂamm Bowel Dis. 2006;12:641-650.
9. Ferwerda G, Girardin SE, Kullberg BJ, et al. NOD2 and toll-like receptors
are nonredundant recognition systems of Mycobacterium tuberculosis.
PLoS Pathog. 2005;1:279-285.
10. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial
muramyl dipeptide mediated through NOD2. Implications for Crohn’s
disease. J Biol Chem. 2003;278:5509-5512. Epub 2003 Jan 4.
11. Mayor NP, Shaw BE, Madrigal JA. NOD2 Polymorphisms and Their
Impact on Haematopoietic Stem Cell Transplant Outcome. Bone
Marrow Res. 2012;2012:180-391.
12. Elmaagacli AH, Steckel N, Ditschkowski M, et al. Toll-like receptor 9,
NOD2 and IL23R gene polymorphisms inﬂuenced outcome in AML
patients transplanted from HLA-identical sibling donors. Bone Marrow
Transplant. 2011;46:702-708.
13. Kreyenberg H, Jarisch A, Bayer C, et al. NOD2/CARD15 gene poly-
morphisms affect outcome in pediatric allogeneic stem cell trans-
plantation. Blood. 2011;118:1181-1184.
14. Holler E, Rogler G, Brenmoehl J, et al. The role of genetic variants of
NOD2/CARD15, a receptor of the innate immune system, in GvHD and
complications following related and unrelated donor haematopoietic
stem cell transplantation. Int J Immunogenet. 2008;35:381-384.
15. Sairaﬁ D, Uzunel M, Remberger M, et al. No impact of NOD2/CARD15
on outcome after SCT. Bone Marrow Transplant. 2008;41:961-964.
16. Gruhn B, Intek J, Pfaffendorf N, et al. Polymorphism of interleukin-23
receptor gene but not of NOD2/CARD15 is associated with graft-
versus-host disease after hematopoietic stem cell transplantation in
children. Biol Blood Marrow Transplant. 2009;15:1571-1577.
17. Nguyen Y, Al-Lehibi A, Gorbe E, et al. Insufﬁcient evidence for associa-
tion of NOD2/CARD15 or other inﬂammatory bowel disease-associated
markers on GVHD incidence or other adverse outcomes in T-replete,
unrelated donor transplantation. Blood. 2010;115:3625-3631.
18. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15)
genotype with clinical course of Crohn’s disease: a cohort study. Lancet.
2002;359:1661-1665.
19. Jaskula E, Dlubek D, Duda D, et al. Interferon gamma 13-CA-repeat
homozygous genotype and a low proportion of CD4(þ) lymphocytes
are independent risk factors for cytomegalovirus reactivation with a
high number of copies in hematopoietic stem cell transplantation re-
cipients. Biol Blood Marrow Transplant. 2009;15:1296-1305.
20. Bewick V, Cheek L, Ball J. Statistics review 8: qualitative data e tests of
association. Crit Care. 2004;8:46-53.
21. Mayor NP, Shaw BE, Madrigal JA, et al. NOD2 Polymorphisms and Their
Impact on Haematopoietic Stem Cell Transplant Outcome. Bone Marrow
Res. 2012;2012:180391. http://dx.doi.org/10.1155/2012/180391.22. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/
CARD15 mutations associate with transplant-related mortality and
GvHD following allogeneic stem cell transplantation. Blood. 2004;104:
889-894.
23. Holler E, Hahn J, Andreesen R, et al. NOD2/CARD15 polymorphisms in
allogeneic stem-cell transplantation from unrelated donors: T deple-
tion matters. J Clin Oncol. 2008;26:338-339. author reply 339.
24. van der Velden WJ, Donnelly JP, Blijlevens NM. Differences in T cell
depletion and intestinal mucositis explain inconsistent effects of
NOD2/CARD15 polymorphisms in SCT. Biol Blood Marrow Transplant.
2011;17:1421-1423.
25. Yomade O, Spies-Weisshart B, Glaser A, et al. Impact of NOD2 poly-
morphisms on infectious complications following chemotherapy in
patients with acute myeloid leukaemia. Ann Hematol. 2013;92:
1071-1077.
26. Tekin D, Dalgic N, Kayaalti Z, et al. Importance of NOD2/CARD15 gene
variants for susceptibility to and outcome of sepsis in Turkish children.
Pediatr Crit Care Med. 2012;13:e73-e77.
27. Brenmoehl J, Herfarth H, Glück T, et al. Genetic variants in the NOD2/
CARD15 gene are associated with early mortality in sepsis patients.
Intensive Care Med. 2007;33:1541-1548.
28. Kramer M, Netea MG, de Jong DJ, et al. Impaired dendritic cell function
in Crohn’s disease patients with NOD2 3020insC mutation. J Leukoc
Biol. 2006;79:860-866.
29. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn’s disease po-
tentiates NF-kappaB activity and IL-1beta processing. Science. 2005;
307:734-738.
30. van Heel DA, Ghosh S, Butler M, et al. Muramyl dipeptide and toll-like
receptor sensitivity in NOD2-associated Crohn’s disease. Lancet. 2005;
365:1794-1796.
31. Barnich N, Aguirre JE, Reinecker HC, et al. Membrane recruitment of
NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}
B activation in muramyl dipeptide recognition. J Cell Biol. 2005;170:
21-26.
32. McDonald C, Chen FF, Ollendorff V, et al. A role for Erbin in the regu-
lation of Nod2-dependent NF-kappaB signaling. J Biol Chem. 2005;280:
40301-40309.
33. Netea MG, Kullberg BJ, de Jong DJ, et al. NOD2 mediates anti-
inﬂammatory signals induced by TLR2 ligands: implications for
Crohn’s disease. Eur J Immunol. 2004;34:2052-2059.
34. Netea MG, Ferwerda G, de Jong DJ, et al. Nucleotide-binding oligo-
merization domain-2 modulates speciﬁc TLR pathways for the induc-
tion of cytokine release. J Immunol. 2005;174:6518-6523.
35. Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of her-
pesviruses by the innate immune system. Nat Rev Immunol. 2011;11:
143-154.
36. Olkinuora H, von Willebrand E, Kantele JM, et al. The impact of early
viral infections and graft-versus-host disease on immune reconstitu-
tion following paediatric stem cell transplantation. Scand J Immunol.
2011;73:586-593.
37. Appleton AL, Sviland L. Pathogenesis of GVHD: role of herpes viruses.
Bone Marrow Transplant. 1993;11:349-355.
38. Wang LR, Dong LJ, Zhang MJ, Lu DP. Correlations of human herpesvirus
6B and CMV infection with acute GVHD in recipients of allogeneic
haematopoietic stem cell transplantation. Bone Marrow Transplant.
2008;42:673-677.
39. Jaskula E, Bochenska J, Kocwin E, et al. CMV serostatus of donor-
recipient pairs inﬂuences the risk of CMV infection/reactivation in
HSCT patients. Bone Marrow Res. 2012;2012:375075.
40. Kim SH, Kee SY, Lee DG, et al. Infectious complications follow-
ing allogeneic stem cell transplantation: reduced-intensity vs.
myeloablative conditioning regimens. Transpl Infect Dis. 2013;15:
49-59.
41. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host
disease prophylaxis: efﬁcacy and side effects. Bone Marrow Transplant.
2005;35:225-231.
42. Viola GM, Zu Y, Baker KR, Aslam S. Epstein-Barr virus-related lym-
phoproliferative disorder induced by equine anti-thymocyte globulin
therapy. Med Oncol. 2011;28:1604-1608.
43. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease.
Semin Hematol. 2006;43:3-10.
44. Ball LM, Egeler RM. EBMT Paediatric Working Party. Acute GvHD:
pathogenesis and classiﬁcation. Bone Marrow Transplant. 2008;
41(Suppl 2):S58-S64.
45. Teira P, Agbalika F, Bergeron A, et al. Primary Epstein-Barr virus
infection with pneumonia transmitted by allogeneic bone marrow
after transplantation. Clin Infect Dis. 2006;43:892-895.
46. Sundin M, Orvell C, Rasmusson I, et al. Mesenchymal stem cells are
susceptible to human herpesviruses, but viral DNA cannot be detected
in the healthy seropositive individual. Bone Marrow Transplant. 2006;
37:1051-1059.
